ArticleJournal of epidemiology and community health2022
Tuberculosis in times of COVID-19.
Article in Journal of epidemiology and community health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial.Antimicrobial agents and chemotherapy · 2023Trial
- Routine Molecular Surveillance of Drug-Resistant Tuberculosis: Translating Mutation Proxies into Clinical Governance Intelligence in Rural Eastern Cape.Healthcare (Basel, Switzerland) · 2026Article
- Comparative evaluation of sputum microscopy and Xpert MTB/RIF assay for tuberculosis detection and rifampicin resistance surveillance in Biratnagar, Nepal.Microbiology spectrum · 2026Article
- The many faces of extrapulmonary tuberculosis: A case series.Journal of family medicine and primary care · 2026Article
- A Point-of-Care Prediction Tool for Recurrent Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- TZ1391: a computationally designed circular mRNA multi-epitope vaccine candidate against Mycobacterium tuberculosis via TLR3 immunomodulation.BMC immunology · 2026Article
- Challenges and Adaptations of TB-DOTS Services during the COVID-19 Pandemic in South Cotabato Province, Philippines: A Mixed Methods Study.Acta medica Philippina · 2026Article
- Mycobacterium tuberculosis transmission in China during the COVID-19 pandemic period (2020-2021) compared with the pre-pandemic period (2017-2019).Nature communications · 2025Article
- Therapeutic potential of Bacillus sonorensis PMC204 membrane vesicles against drug-resistant Mycobacterium tuberculosis.Medical microbiology and immunology · 2025Article
- Spatiotemporal distribution and detection of spatial clusters of tuberculosis in Hubei Province, China using FleXScan (2017-2023).BMC public health · 2025Article
- Impact of the COVID-19 pandemic on tuberculosis program performance in Alberta, Canada: a population-based evaluation.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Article
- Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital.Infectious disease reports · 2025Article
- Advanced Therapeutic Interventions TargetingArchives of Razi Institute · 2025Review
- Health and tuberculosis systems resilience, the role of the private sector and pandemic preparedness: insights from a cross-country qualitative study with policy-makers in India, Indonesia and Nigeria.BMJ global health · 2025Article
- COVID-19, tuberculosis, and HIV triad: a prospective observational study in ambulatory patients in Kenya, Uganda, and South Africa.PLOS global public health · 2025Article
- Thyroid Tuberculosis: Misdiagnosed as Papillary Thyroid Carcinoma - A Rare Case Report.International medical case reports journal · 2025Article
- A Review of Workplace Tuberculosis Policies in Selected Low- and Middle-Income Countries in Asia-Pacific.Acta medica Philippina · 2025Article
- COVID-19 Vaccine Uptake: Prevalence, Health Facility Enablers and Barriers among Adult Tuberculosis Patients across Nairobi County Clinics, Kenya.Journal of tuberculosis research · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has caused widespread disruptions to tuberculosis (TB) care and service delivery in 2020, setting back progress in the fight against TB by several years. As newer COVID-19 variants continue to devastate many low and middle-income countries in 2021, the extent of this setback is likely to increase. Despite these challenges, the TB community can draw on the comprehensive approaches used to manage COVID-19 to help restore progress and mitigate the impact of COVID-19 on TB. Our team developed the 'Swiss Cheese Model for Ending TB' to illustrate that it is only through multisectoral collaborations that address the personal, societal and health system layers of care that we will end TB. In this paper, we examine how COVID-19 has impacted the different layers of TB care presented in the model and explore how we can leverage some of the lessons and outcomes of the COVID-19 pandemic to strengthen the global TB response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.